Healthcare Business

Revolution Medicines Enters the Market With a Bang

Revolution Medicines Inc. (NASDAQ: RVMD) entered the market with a bang on Thursday. Although the company only priced shares are $17 apiece, the stock actually entered the market closer to ...
Read Full Story »

Is CVS Back on Track With Q4 Results?

When CVS Health Corp. (NYSE: CVS) reported its most recent quarterly results before the markets opened on Wednesday, the pharmacy chain posted $1.73 in earnings per share (EPS) and $66.9 ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Biotech Short Sellers Focus on a Couple Favorites

The short interest data are out for the most recent settlement date, January 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Is CVS Set to Wow Investors With Q4 Earnings Wednesday Morning?

CVS Health Corp. (NYSE: CVS) is set to report its fourth-quarter financial results before the markets open on Wednesday. The drugstore, pharmacy benefits manager and health insurer has faced strong ...
Read Full Story »

5 Big Dividend Pharmaceutical Stocks to Buy as Health Care Could Explode Higher

For years, one of the most dependable sectors, especially for more conservative investors, was health care, which included the top pharmaceutical and biotech stocks among other holdings. However, over the ...
Read Full Story »

Moderna Commits to $500 Million Capital Raise, With More Possible

Moderna Inc. (NASDAQ: MRNA) had been the biggest biotech initial public offering ever. The company was quite unlucky in the timing for its IPO, but it managed to get back ...
Read Full Story »

When Will Amarin Stock Sell-Off Be Over?

Amarin Corp. PLC (NASDAQ: AMRN) is a biotechnology company based in Ireland. Among its specialties, the company claims, it does research and development (R&D) work on polyunsaturated fatty acid and ...
Read Full Story »

Why This Acquisition Could Be Huge for Collegium Pharma

Collegium Pharmaceutical Inc. (NASDAQ: COLL) shares popped on Friday after the firm announced that it will acquire the U.S. rights to the Nucynta franchise from Assertio Therapeutics. The deal is ...
Read Full Story »

AbbVie Wows Again With Q4 Results

When AbbVie Inc. (NYSE: ABBV) released its fourth-quarter financial results before the markets opened on Friday, the pharmaceutical giant said that it had $2.21 in earnings per share (EPS) and ...
Read Full Story »

PPD Proves Optimistic in IPO Debut

PPD Inc. (NASDAQ: PPD) made an exciting entrance to the market Thursday. The company priced its shares at $27 apiece, at the high end of the expected price range of ...
Read Full Story »

Why This First of Its Kind Anaphylaxis Treatment Could Be Huge

Aquestive Therapeutics Inc. (NASDAQ: AQST) shares jumped on Thursday after the firm announced that it had a constructive face-to-face pre-Investigational New Drug (IND) application meeting with the U.S. Food and ...
Read Full Story »

Merck’s Spin-Off May Create Operational Risks for the Year Ahead

In recent years, investors frequently have run into issues being invested in major pharmaceutical companies. On top of drug pricing concerns brought up in endless political debates, many of the ...
Read Full Story »

Why This FDA Approval Is a Big Win for Vivus

Vivus Inc. (NASDAQ: VVUS) shares jumped on Wednesday after the company announced a crucial approval by the U.S. Food and Drug Administration (FDA). Specifically, the FDA approved the company's supplemental ...
Read Full Story »

Is Merck Stuck in the Slow Lane?

Merck & Co. Inc. (NYSE: MRK) reported its fourth-quarter financial results before the markets opened on Wednesday. The pharmaceutical giant said that it had $1.16 in EPS and $11.9 billion ...
Read Full Story »